Diabetes Research Centers (P30 Clinical Trial Optional)

The summary for the Diabetes Research Centers (P30 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Diabetes Research Centers (P30 Clinical Trial Optional): This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P and F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Federal Grant Title:	Diabetes Research Centers (P30 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition, Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-25-008
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 18th, 2024
Original Application Deadline:	June 18th, 2024
Posted Date:	March 29th, 2024
Creation Date:	March 29th, 2024
Archive Date:	July 24th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	March 29th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-008.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies ...; • NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements...; • Limited Competition: Small Grant Program for NIDDK K01/K08/K23/K25 Recipients (R03 Clinica...; • Small R01s for Clinical Trials Targeting Diseases within the Mission of NIDDK (R01 Clinica...; • Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogen...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • NIA Predoctoral Fellowship Award to Promote Broad Participation in Translational Research ...; • NIA Postdoctoral Fellowship Award to Promote Broad Participation in Translational Research...; • Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) ...; • Limited Competition: Clinical Research Sites (CRS) for the MACS/WIHS Combined Cohort Study...; • Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)